VanessaLynnDickeyMD

Hematology • Torrance, CA

Clotting Disorder, Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Oncology Chair; Providence Little Company of Medicine

Join to view full profile

Dr. Dickey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dickey's full profile

Already have an account?

Office
Hunt Cancer Center
3285 Skypark Drive
Torrance, CA 90505
Phone+1 310-750-3300

Fax+1 310-750-3300
Is this information wrong?

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2002 - 2003
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2000 - 2002
Santa Barbara Cottage HospitalResidency, Internal Medicine, 1997 - 2000
Eastern Virginia Medical SchoolClass of 1997

Certifications & Licensure

CA State Medical License 2003 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Start of enrollment: 2009 Oct 01
Completed
Phase 2
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Start of enrollment: 2013 Apr 01
Terminated
Phase 3
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Start of enrollment: 2014 Sep 30
Completed
Phase 3
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label Start of enrollment: 2014 Nov 01
Terminated
Phase 2
Join now to see all

Press Mentions

Holistic Help for Serious IllnessAugust 3rd, 2021

Hospital Affiliations

Torrance Memorial Medical CenterTorrance, California